NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
03/19/2024
Back to search
Official data from USPTO
ACT ALBUQUERQUE CLINICAL TRIALS A CENTER FOR CLINICAL RESEARCH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
03/20/2024
Trademark type
Combined
Nice classes
42
Filing date
04/17/2017
Registration date
02/27/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/19/2024
Last transaction
03/20/2024
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Principal Register
First use anywhere
05/13/2016
First use in commerce
05/13/2016
Drawing code
3
Owner type
03
Owner location
Albuquerque, NM
Examiner
ERVIN, INGA
Law office
M20
Current location
TMO LAW OFFICE 111
Mark description
The mark consists of an outline of a microscope in a circular design with a plus on the right side of the microscope. To the right of the design, is the wording "Albuquerque Clinical Trials" and the wording "A Center for Clinical Research" in text below.
Holders and representatives
Holders
Albuquerque Clinical Trials, Inc.
Representatives
Albuquerque Clinical Trials, Inc.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Medical and scientific researchconducting clinical trials for others
Publications
History of USPTO decisions and trademark events.
26 publications found
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
03/19/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/19/2024
ES8R
TEAS SECTION 8 RECEIVED
01/08/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
02/27/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
02/27/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/12/2017
PUBO
PUBLISHED FOR OPPOSITION
12/12/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/22/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/04/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/03/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
11/03/2017
ALIE
ASSIGNED TO LIE
11/02/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/02/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
11/02/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/02/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/31/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/31/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/31/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/19/2017
GNRT
NON-FINAL ACTION E-MAILED
07/19/2017
CNRT
NON-FINAL ACTION WRITTEN
07/19/2017
DOCK
ASSIGNED TO EXAMINER
07/11/2017
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
04/25/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/24/2017
NWAP
NEW APPLICATION ENTERED
04/20/2017
Continuous trademark protection
Get notified about every new filing that threatens ACT ALBUQUERQUE CLINICAL TRIALS A CENTER FOR CLINICAL RESEARCH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.